Shares of Pfizer Inc. (NYSE:PFE) have earned a consensus rating of “Buy” from the twenty-one analysts that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $38.70.
Several brokerages have commented on PFE. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Friday. Deutsche Bank set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Barclays set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. Finally, Jefferies Group set a $38.00 price objective on Pfizer and gave the company a “neutral” rating in a research report on Monday, October 16th.
Shares of Pfizer (NYSE PFE) traded down $0.19 during trading on Friday, reaching $36.94. The company’s stock had a trading volume of 14,017,205 shares, compared to its average volume of 19,924,580. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The stock has a market capitalization of $221,708.50, a price-to-earnings ratio of 14.88, a P/E/G ratio of 2.63 and a beta of 1.01. Pfizer has a fifty-two week low of $30.90 and a fifty-two week high of $37.35.
Pfizer declared that its board has initiated a stock repurchase program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.68%. The ex-dividend date of this dividend is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is currently 79.01%.
In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the transaction, the insider now directly owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. In the last three months, insiders sold 36,800 shares of company stock valued at $1,327,248. 0.06% of the stock is owned by insiders.
Large investors have recently modified their holdings of the business. Altfest L J & Co. Inc. grew its stake in shares of Pfizer by 67.0% during the 2nd quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock valued at $3,603,000 after purchasing an additional 43,024 shares during the period. HL Financial Services LLC grew its stake in shares of Pfizer by 1.1% during the 2nd quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock valued at $108,260,000 after purchasing an additional 35,744 shares during the period. Sphera Funds Management LTD. bought a new stake in shares of Pfizer during the 1st quarter valued at about $13,342,000. Searle & CO. grew its stake in shares of Pfizer by 92.7% during the 1st quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock valued at $2,739,000 after purchasing an additional 38,500 shares during the period. Finally, Hartford Financial Management Inc. grew its stake in shares of Pfizer by 10.8% during the 2nd quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 835 shares during the period. 69.75% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Analysts Set Pfizer Inc. (PFE) Price Target at $38.70” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://sportsperspectives.com/2017/12/19/analysts-set-pfizer-inc-pfe-price-target-at-38-70.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.